Isocitrate Dehydrogenase

"Isocitrate Dehydrogenase" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

An enzyme of the oxidoreductase class that catalyzes the conversion of isocitrate and NAD+ to yield 2-ketoglutarate, carbon dioxide, and NADH. It occurs in cell mitochondria. The enzyme requires Mg2+, Mn2+; it is activated by ADP, citrate, and Ca2+, and inhibited by NADH, NADPH, and ATP. The reaction is the key rate-limiting step of the citric acid (tricarboxylic) cycle. (From Dorland, 27th ed) (The NADP+ enzyme is EC 1.1.1.42.) EC 1.1.1.41.

Descriptor ID	D007521
MeSH Number(s)	D08.811.682.047.820.475
Concept/Terms	Isocitrate Dehydrogenase Isocitrate Dehydrogenase Dehydrogenase, Isocitrate NAD Isocitrate Dehydrogenase Dehydrogenase, NAD Isocitrate Isocitrate Dehydrogenase, NAD Isocitrate Dehydrogenase (NAD+) Isocitrate Dehydrogenase-I Isocitrate Dehydrogenase-I Isocitrate Dehydrogenase I

Below are MeSH descriptors whose meaning is more general than "Isocitrate Dehydrogenase".

Chemicals and Drugs [D]
Enzymes and Coenzymes [D08]
Enzymes [D08.811]
Oxidoreductases [D08.811.682]
Alcohol Oxidoreductases [D08.811.682.047]
NAD (+) and NADP (+) Dependent Alcohol Oxidoreductases [D08.811.682.047.820]
Isocitrate Dehydrogenase [D08.811.682.047.820.475]

Below are MeSH descriptors whose meaning is related to "Isocitrate Dehydrogenase".

Below are MeSH descriptors whose meaning is more specific than "Isocitrate Dehydrogenase".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Isocitrate Dehydrogenase" by people in this website by year, and whether "Isocitrate Dehydrogenase" was a major or minor topic of these publications.

Bar chart showing 18 publications over 10 distinct years, with a maximum of 3 publications in 2002 and 2020

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2002	3	0	3
2003	2	0	2
2004	2	0	2
2005	2	0	2
2006	2	0	2
2007	1	0	1
2010	1	0	1
2013	1	0	1
2020	1	2	3
2023	0	1	1

Below are the most recent publications written about "Isocitrate Dehydrogenase" by people in Profiles.

Miller JJ, Gonzalez Castro LN, McBrayer S, Weller M, Cloughesy T, Portnow J, Andronesi O, Barnholtz-Sloan JS, Baumert BG, Berger MS, Bi WL, Bindra R, Cahill DP, Chang SM, Costello JF, Horbinski C, Huang RY, Jenkins RB, Ligon KL, Mellinghoff IK, Nabors LB, Platten M, Reardon DA, Shi DD, Schiff D, Wick W, Yan H, von Deimling A, van den Bent M, Kaelin WG, Wen PY. Isocitrate dehydrogenase (IDH) mutant gliomas: A Society for Neuro-Oncology (SNO) consensus review on diagnosis, management, and future directions. Neuro Oncol. 2023 01 05; 25(1):4-25.

View in: PubMed
Asioli S, Ruengwanichayakun P, Zoli M, Guaraldi F, Sollini G, Greco P, Facco C, Gibertoni D, Jim?nez BV, Benini S, Turri-Zanoni M, Pasquini E, Mazzatenta D, Foschini MP, Righi A. Association of Clinicopathological Features With Outcome in Chondrosarcomas of the Head and Neck. Otolaryngol Head Neck Surg. 2021 04; 164(4):807-814.

View in: PubMed
Gambarotti M, Pacheco M, Ruengwanichayakun P, Silvino Vega Jim?nez B, Benini S, Bianchi G, Sbaraglia M, Vanel D, Carretta E, Bertoni F, Franchi A, Dei Tos AP, Righi A. Synovial chondrosarcoma: a single-institution experience with molecular investigations and review of the literature. Histopathology. 2020 Sep; 77(3):391-401.

View in: PubMed
Abou-Alfa GK, Macarulla T, Javle MM, Kelley RK, Lubner SJ, Adeva J, Cleary JM, Catenacci DV, Borad MJ, Bridgewater J, Harris WP, Murphy AG, Oh DY, Whisenant J, Lowery MA, Goyal L, Shroff RT, El-Khoueiry AB, Fan B, Wu B, Chamberlain CX, Jiang L, Gliser C, Pandya SS, Valle JW, Zhu AX. Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2020 06; 21(6):796-807.

View in: PubMed
Shields JA, Shields CL. Reactive retinal astrocytic tumors (so-called vasoproliferative tumors): histopathologic, immunohistochemical, and genetic studies of four cases. Am J Ophthalmol. 2013 Jul; 156(1):202-3.

View in: PubMed
Dange M, Colman RF. Each conserved active site tyr in the three subunits of human isocitrate dehydrogenase has a different function. J Biol Chem. 2010 Jul 2; 285(27):20520-5.

View in: PubMed
Bzymek KP, Colman RF. Role of alpha-Asp181, beta-Asp192, and gamma-Asp190 in the distinctive subunits of human NAD-specific isocitrate dehydrogenase. Biochemistry. 2007 May 8; 46(18):5391-7.

View in: PubMed
Soundar S, O'hagan M, Fomulu KS, Colman RF. Identification of Mn2+-binding aspartates from alpha, beta, and gamma subunits of human NAD-dependent isocitrate dehydrogenase. J Biol Chem. 2006 Jul 28; 281(30):21073-81.

View in: PubMed
Lee P, Colman RF. Thr373, Asp375, and Lys260 are in the coenzyme site of porcine NADP-dependent isocitrate dehydrogenase. Arch Biochem Biophys. 2006 Jun 15; 450(2):183-90.

View in: PubMed
Huang YC, Colman RF. Location of the coenzyme binding site in the porcine mitochondrial NADP-dependent isocitrate dehydrogenase. J Biol Chem. 2005 Aug 26; 280(34):30349-53.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement